Boehringer Ingelheim GmbH
Binger Str. 173
99 articles with Boehringer Ingelheim GmbH
First, and only, flea and tick product approved by the FDA to prevent Borrelia burgdorferi infections in dogs by killing black-legged ticks.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership to Develop First-in-Class Gene Therapy for Cystic Fibrosis
This new collaboration unites leaders in cystic fibrosis gene therapy, lentiviral development and production, and the treatment of respiratory diseases to develop the first gene therapy for cystic fibrosis.
Boehringer Ingelheim Invests More Than €200 Million to Establish Strategic Production Center for Veterinary Public Health in France
With this new site, the company will be able to respond to the growing global demand for foot-and-mouth disease and Bluetongue virus control
MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers
MabVax Therapeutics Holdings, Inc. announced they have signed an asset acquisition and related agreements centered on MabVax's program targeting a glycan commonly overexpressed on multiple solid tumor cancers. Boehringer Ingelheim has acquired all rights in and to the program.
Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.
Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec.
Hydra Biosciences Release: TRPC4/5 Inhibitor Now Investigated in Clinic for Central Nervous System Disorders
Hydra Biosciences announced today that Boehringer Ingelheim has initiated a Phase 1 clinical trial in healthy volunteers to evaluate a TRPC4/5 inhibitor compound for the treatment of CNS diseases and disorders including depression and anxiety.
iPharma Enters Into Licensing Agreement With Boehringer Ingelheim to Obtain Worldwide Rights to FAK Inhibitor Oncology Development Program
iPharma, Ltd. announced today that it has entered into an exclusive worldwide license agreement with Boehringer Ingelheim.
Dicerna and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases.
TARGET PharmaSolutions is pleased to announce that Boehringer Ingelheim has entered into a multi-year strategic partnership for TARGET-NASH.
Boehringer Ingelheim GmbH Release: FDA Medicare Study In 134,000 Atrial Fibrillation Patients Confirms Positive Safety Profile And Effectiveness Of Pradaxa® In General Practice
Boehringer Ingelheim GmbH Release: Type 2 Diabetes: Physicians Worldwide Agree Early Conversations Are Crucial In The Management Of Condition
Boehringer Ingelheim GmbH Release: New Study To Investigate Dabigatran Etexilate For Prevention Of Recurrent Stroke In High-Risk Patients
Boehringer Ingelheim GmbH Release: Better Outcome in Case of Major Bleed for Patients Taking the Anticoagulant Pradaxa® Compared to Warfarin
Boehringer Ingelheim GmbH Release: Data Presented at EASD Support Safety Profile of Trajenta® (Linagliptin) In Broad Range of Adults With Type 2 Diabetes
Swedish Orphan Biovitrum Gets FDA Approval to Manufacture Substance for Kineret® With Partner Boehringer Ingelheim Corporation
Boehringer Ingelheim GmbH and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions®
Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation